Heesom A E, Millward A, Demaine A G
Molecular and Biomedical Sciences, Plymouth Postgraduate Medical School, University of Plymouth, UK.
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):213-6. doi: 10.1136/jnnp.64.2.213.
There is evidence that the polyol pathway is involved in the pathogenesis of diabetic neuropathy. Aldose reductase (ALR2) is the first and rate limiting enzyme of this pathway and recent studies have suggested that polymorphisms in and around the gene are associated with the development of diabetic microvascular disease. The aim was to examine the role of ALR2 in the susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus (IDDM).
One hundred and fifty nine British white patients with IDDM and 102 normal healthy controls were studied using the polymerase chain reaction to test for a highly polymorphic microsatellite marker 2.1 kilobase (kb) upstream of the initiation site of the ALR2 gene.
Seven alleles were detected (Z-6, Z-4, Z-2, Z, Z+2, Z+4, and Z+6). There was a highly significant decrease in the frequency of the Z+2 allele in those patients with overt neuropathy compared with those with no neuropathy after 20 years duration of diabetes (14.1% v 38.2%, chi2 =17.3, p<0.00001). A similar difference was also found between the neuropathy group and those patients who have had diabetes for < five years with no overt neuropathy (14.1% v 30.2%, chi2=9.0, p<0.0025). The neuropathy group also had a significant decrease in the frequency of the Z/Z+2 genotype compared with those patients who have no neuropathy after 20 years duration of diabetes (14.0% v 44.7%, chi2=13.0, p<0.0005).
These results suggest that the aldose reductase gene is intimately involved in the pathogenesis of diabetic neuropathy.
有证据表明多元醇途径参与糖尿病神经病变的发病机制。醛糖还原酶(ALR2)是该途径的首个限速酶,近期研究表明该基因及其周围的多态性与糖尿病微血管病变的发生有关。目的是研究ALR2在胰岛素依赖型糖尿病(IDDM)患者发生糖尿病神经病变易感性中的作用。
对159例英国白人IDDM患者和102例正常健康对照者进行研究,采用聚合酶链反应检测ALR2基因起始位点上游2.1千碱基(kb)处的一个高度多态性微卫星标记。
检测到7个等位基因(Z-6、Z-4、Z-2、Z、Z+2、Z+4和Z+6)。糖尿病病程达20年后,有明显神经病变的患者中Z+2等位基因频率与无神经病变者相比显著降低(14.1%对38.2%,χ²=17.3,p<0.00001)。神经病变组与糖尿病病程<5年且无明显神经病变的患者之间也发现了类似差异(14.1%对30.2%,χ²=9.0,p<0.0025)。与糖尿病病程20年后无神经病变的患者相比,神经病变组Z/Z+2基因型频率也显著降低(14.0%对44.7%,χ²=13.0,p<0.0005)。
这些结果表明醛糖还原酶基因与糖尿病神经病变的发病机制密切相关。